Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Details : ABvac40 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cognitive Dysfunction.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 12, 2018
Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients
Details : ABvac40 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 14, 2017
Reset All
